fbpx Skip to main content

THURSDAY, Oct. 29, 2020 (HealthDay News) — To make health care costs more transparent, the Trump administration will now require insurance companies to disclose actual prices for common tests and procedures, the Associated Press reported.

The new regulations on insurers are designed to empower patients to become better consumers of health care and to help cut costs. The requirements, however, would take effect over four years and patients will have to figure out how to make cost-versus-quality decisions about procedures like knee replacements or hernia repairs, the AP reported.

It is also not known what would happen to the policy if Trump is not reelected. Administration officials, however, say the changes will stand, saying that the goal of price transparency transcends political partisanship. “It will be impossible to walk backwards on this,” Health and Human Services Secretary Alex Azar told the AP. “How do you fight transparency on prices? How do you actually articulate the argument that you should conceal what something costs from the person trying to purchase it?”

Insurance companies argue that the rules actually increase costs. Hospitals and doctors that now accept discounted rates will want to get paid more once they see what their competitors are getting, the AP reported. Most patients only find out what they owe after they leave the hospital and receive their “explanation of benefits” statement.

“We need to keep pricing on the front end, not the back end,” Seema Verma, head of the Centers for Medicare & Medicaid Services, told the AP. “We have seen in every single industry that when this information is provided to consumers, it creates a new era of consumerism.”

You May Also Like::  No Pfizer COVID-19 Vaccine Expected Before Election

AP News Article

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More